PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30012495-10 2018 In our studies, myricetin-induced increment of ALP activity was decreased by ERK (PD98059), JNK (SP600125), p38 (SB203580), and Smad 1/5/9 (LDN193189) inhibitors. pyrazolanthrone 97-105 alkaline phosphatase, placental Homo sapiens 47-50 28833827-14 2017 Furthermore, inhibition of JNK by its inhibitor SP600125 dramatically blocked POSTN-enhanced scratch closure, ALP activity and mineralization in PDLSCs. pyrazolanthrone 48-56 alkaline phosphatase, placental Homo sapiens 110-113 28052093-4 2017 Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs. pyrazolanthrone 65-73 alkaline phosphatase, placental Homo sapiens 312-332 28052093-4 2017 Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs. pyrazolanthrone 65-73 alkaline phosphatase, placental Homo sapiens 334-337 23657597-6 2013 Among the periosteal-derived cells pretreated with MAPK inhibitors, the ALP activity was markedly decreased in the cells pretreated with SP 600125, the specific inhibitor of C-Jun N-terminal kinase (JNK). pyrazolanthrone 137-146 alkaline phosphatase, placental Homo sapiens 72-75 27959394-6 2017 The use of JNK inhibitor (SP600125) enhanced the inhibitory effects of miR-214 overexpression on osteogenic differentiation, ALP activity, and Col I, OCN and OPN gene expression in the BMSCs. pyrazolanthrone 26-34 alkaline phosphatase, placental Homo sapiens 125-128 27484838-11 2016 Furthermore, inhibition of JNK by its inhibitor, SP600125, or MEK/Erk signalling by its inhibitor, PD98059, dramatically blocked IGFBP5-enhanced ALP activity and in vitro mineralization in both PDLSCs and WJCMSCs. pyrazolanthrone 49-57 alkaline phosphatase, placental Homo sapiens 145-148 27106512-9 2016 The amentoflavone-induced increases of ALP and mineralization were significantly diminished when the JNK and p38 MAPK pathways were blocked by selected inhibitors (SP600125, SB203580) in hMSCs. pyrazolanthrone 164-172 alkaline phosphatase, placental Homo sapiens 39-42 26879145-9 2016 Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively. pyrazolanthrone 73-81 alkaline phosphatase, placental Homo sapiens 32-35 25994505-8 2015 In addition, addition of SP600125 or SB203580 also blocked apigenin-induced ALP activity, OPN, Runx2, and OSX expression and meanwhile inhibited bone nodule formation. pyrazolanthrone 25-33 alkaline phosphatase, placental Homo sapiens 76-79